New hope for Hard-to-Treat lymphoma: drug cocktail enters human trials
NCT ID NCT07159906
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) in 62 adults with relapsed or refractory diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combo can shrink tumors. It's an early-phase trial, so results will guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Homoharringtonine, Lisaftoclax (BCL-2 inhibitor), Rituximab, and Prednisone
What this could lead to
If this works, it could offer a new treatment option for people with hard-to-treat lymphoma who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 62 people, so it's too soon to know if the combination is safe or effective. Side effects from the drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China